Shorties getting nervous..lol!

Great results. Big pharma is likely impressed although SP manipulators seem to be enjoying themselves today! Be glad to get into some volume from investors that want to hold for more than a quarter at a time!

LEXX was unsuccessful with CBD because it wasn't clinically tested and approved for a particular medical affliction. The idea with the oral Liraglutide and/ or CBD for Hypertension is the drugs, after testing and approval, would be the only oral drugs of their kinds in the world and could be subscribed by doctors for whatever they are approved to treat. i.e. hypertension, weight loss, T2 diabetes amongst many other afflictions being discovered all the time! IMO It's definitely a good side bet for them.
https://lexariabioscience.com/2025/02/20/lexarias-strategic-business-pursuit-of-dehydratech-liraglutide/

https://lexariabioscience.com/2025/02/11/lexaria-granted-two-new-dehydratech-patents-for-treatment-of-epilepsy/

Big milestone!! First ever Lexaria clinical study has begun! Great news.

https://s3.amazonaws.com/sec.irpass.cc/2978/0001348362-24-000006.htm

New drugs coming on line that could be improved with DehydraTECH.

It's a study, only it's through a Contract Research Organization as opposed to just using a "plain" Lab. The CRO helps make sure the study is done towards gaining accreditation with clinical trials and FDA whereas a "plain" lab does not. Lexaria will be paying more for this than a "plain" study because of the extra value it will attain but as usual, with all studies, the cost is not announced.

Yeah, why would they want to make massive piles of money being hugely successful when they could fart around all day and potentially go broke?

https://lexariabioscience.com/2024/11/14/lexaria-signs-contract-for-new-dehydratech-glp-1-biodistribution-study/

https://lexariabioscience.com/2024/11/13/ethics-board-approval-granted-for-lexarias-12-week-phase-1b-dehydratech-glp-1-study-in-diabetes-and-weight-loss/

Possibly the reason we're not seeing deals being made recently is because of the temporary exclusivity we have given the global pharma company in the MTA: "Lexaria has awarded to PharmaCO a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination".
This would mean LEXX has to turn potential deals down until a decision has been made with this MTA.
Hopefully the MTA is with a Big PharmaCO and not little pharmaco and the studies go well.

Viking's pill is in Phase2 clinical trials right now so may not even make it as a product. But if it does they could try make it better by using DehydraTech!

https://ir.lexariabioscience.com/news-events/press-releases/detail/273/positive-partial-12-week-body-weight-results-from

Worked fine for me!

4 months is closer as he took on a more specific role for LEXX as shown in the July NR below:
"Lexaria will be expanding its management team this summer as it prepares for the greater workload of multiple projects and initiatives. The first step is appointing Nelson Cabatuan as our consulting Chief Strategic Financial Advisor, in order to maximize his skills in the fields of corporate finance and strategic industry relationships and opportunities. Nelson is resigning from his current role as Chief Financial Officer (CFO) in order to better focus on the strategic opportunities afforded to the Company outside of typical accounting tasks. Our new CFO will be appointed and announced in due course".
https://ir.lexariabioscience.com/news-events/press-releases/detail/257/lexaria-preparing-for-strategic-growth

Oral GLP-1 going to OTC could really open up the market for LEXX to get product up and running sooner than ever! The huge interest across the board is super positive. Thanks for posting this.

https://ir.lexariabioscience.com/news-events/press-releases/detail/266/lexaria-releases-strategic-letter-from-the-outgoing-ceo

Seems like just a "cover your ass" transparency PR in case after a deal is made folks wonder why nothing was said about it earlier. Could be a nothing burger or a feast...time will tell.

https://ir.lexariabioscience.com/news-events/press-releases/detail/264/lexaria-enters-a-material-transfer-agreement-for

Shawking posted it a few weeks ago. https://mcusercontent.com/f2e0706764f99154e3a11feb5/files/6ccd2935-adf3-244c-cd2f-872cd1ffd732/530Let_039_sTokeBusinessJune282024.asd.pdf

https://ir.lexariabioscience.com/news-events/press-releases/detail/251/lexaria-receives-two-new-medical-treatment-patents-in

Back to $70/sh !! Sounds good. Make it happen. lol

May I remind you of your last post 3 weeks ago..
"The next leg up will be 5-8 million daily volume and price, which is going 300-400%from these levels".
Something is wrong with your calculations making it a bit hard to trust them!

and it's still being bought as it does!

https://ir.lexariabioscience.com/news-events/press-releases/detail/244/lexaria-appoints-nelson-cabatuan-as-chief-financial-officer

Executive compensation is obviously on our backs as well as studies and patents etc. but IMO the pros outdo the cons and that's why I'm still here. It's easy to imagine we're not getting enough bang for our bucks until we get proven otherwise. I like to think: Would I like to do Bunka's job for the amount he gets paid and the answer is a huge "No"! You couldn't pay me enough because I'm sure he has sacrificed a lot in his personal life. I'm okay with the amount our leaders are taking as I can see progress. I wish it was faster but gotta stay patient if I want to land some Big Pharma bucks!

This is typical for an R&D company that doesn't have much revenue. Hopefully everyone's averaged down enough they can absorb supporting the company as you mentioned.

LEXX does not commit fraud or they would be quickly out of business. You can't trust posters on these online bull boards to tell the truth. Everyone has their own agenda. Think about how the individual posts might benefit the individual if taken as verbatim! Read between the lines and Do Your own Due Diligence through other sources besides the bull boards. Good Luck.

I just read through the S-1 just issued and I don't see where it says the warrants have been exercised. Not that they haven't been. I'm not sure how you know this. Could you provide a link of some sort? Also, where is it written in the offering or elsewhere that exercised warrants have a 6 month holding period. Not trying to argue...just want to understand this. Thanks.

Real classy there Harlem! Blocking now!

AKA right after an offering where warrants are immediately exercisable and there's an obvious spike caused by pump and dump info flooding the media...be more careful , lol.

The beauty of DehydraTECH is that LEXX can almost always improve any lipophillic drug. A large pharma company could be using DehydraTECH with a great many of their products and keep using it for new ones as they are approved!

LEXX hasn't been above $6 since Nov. 2021 !

https://ir.lexariabioscience.com/news-events/press-releases/detail/241/7-weight-loss-in-animals-supports-lexarias-next-8-week

and that now gives them an $8.5 Billion Market Cap!! Last Oct. they were at $10 now $85!

All Institutional ownership results by the end of Dec '23 add up to just less than 11%!! Insiders own 6%. Things have obviously changed in the last 6 weeks but haven't seen anyone claiming a new 13D - 5% ownership filing this year!
https://www.nasdaq.com/market-activity/stocks/lexx/institutional-holdings

Maybe they got accepted and just haven't released it yet. They can't start the trials until 30 days after the application but it doesn't mean the FDA needs that whole 30 days to evaluate the application! I see the acceptance being issued very soon! - I think LEXX wouldn't raise the $ if they weren't sure they needed it!

Nice move. Clinical trials, here we come!!

Wayne Boos reporting 480,000 shares owned at EOY - up 30,000 from Sept 30, '23.
https://ir.lexariabioscience.com/sec-filings/all-sec-filings##document-1915-0001235126-24-000010-2

(a) As of December 31, 2023, Wayne W. Boos beneficially owns
a total of 480,000 shares of the Companys Common Stock which
represent approximately 4.67078% of the outstanding Common Stock,
based on 10,276,641 Common Stock outstanding as of November 20, 2023,
as indicated by the Company. The percentage of Mr. Boos ownership of
Common Stock in the Company has varied since the filing of this
Schedule 13D as Mr. Boos has (i) purchased additional shares of the
Companys Common Stock, (ii) he has sold shares of the Companys
Common Stock, and (iii) the Company has issued additional shares of
Common Stock.

(b) Nature of Ownership. Wayne W. Boos has the sole power to
vote and direct the disposition of all of the 480,000 shares
reported as beneficially owned by him.

(c) Recent Transactions. In the 60 days prior to
December 31, 2023, Wayne W. Boos (i) sold 30,000 shares of the
Companys Common Stock for an average price per share of $1.31
and (ii) acquired 90,000 shares of the Companys Common Stock
for an average price per share of $1.405597 through his broker,
Merrill Lynch.

(d)No other person has the right to receive or the power to
direct the receipt of the dividends from, or proceeds from the
sale of, such securities.

(e) Wayne W. Boos ceased to be the beneficial owner of more than
five percent of the Companys Common Stock on or about
October 3, 2023, when the Company issued additional
shares of the Companys Common Stock.